The times they are a changin' for the players across pharmaceutical supply chains, from API suppliers to CMOs, to manufacturers, packagers, distributors, dispensers/pharmacies ... just about everyone across the chain.
Compliance is at a tipping point. The role of the chief compliance officer has gained more prominence over the last decade and is evolving rapidly. Today's CCOs are in a position similar to that of CFOs 15 years ago, and face a similar opportunity and challenge: how to become a more strategic partner in the organization, a vital member of the C-suite.
Analyst Insight: If 2012 was the year of climbing the emerging market mountain, then 2013 was the cliff. Not just for patents, but also in succeeding across multiple global markets. Quality issues, bad business practices, failure to integrate acquisitions, these were all common threads. Reputable players stumbled. Lesson learned: focusing on core business is the key to success. Many smaller non-core acquisitions such as animal health, devices, and OTC products will continue to spin off. Emerging and core markets will focus on profitability and smart growth, not just volume. - Brian Hudock, Partner, Tompkins International